文献速递白血病造血干细胞移植与细胞治疗

青少年及青年急性髓系白血病清髓性异基因造血干细胞移植后的远期效应

Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究评估了826例因急性髓系白血病接受清髓性异基因造血干细胞移植的青少年及青年1年无病生存者的远期效应与生存,并比较了全身照射与单纯大剂量化疗两种预处理方案。结果显示远期效应常见,10年后续肿瘤累积发生率为4%,且远期效应更多与慢性移植物抗宿主病相关而非预处理类型。

要点

  • 10年后续肿瘤累积发生率为4%,无病生存者远期效应常见。
  • 慢性GVHD与白内障、股骨头坏死和糖尿病风险增加相关。
  • 全身照射仅与白内障风险升高独立相关,10年生存不受预处理类型影响。

核心结论

  • 青少年及青年急性髓系白血病清髓性移植后远期效应常见,且与慢性GVHD关联更密切而非预处理类型。

研究设计与样本

  • 回顾性评估826例因急性髓系白血病接受清髓性异基因造血干细胞移植的青少年及青年1年无病生存者,比较全身照射与单纯大剂量化疗的远期效应。

主要发现

  • 10年后续肿瘤累积发生率为4%(95%CI 2%-6%)。
  • 10年非恶性远期效应累积发生率:性腺功能障碍10%(95%CI 8%-13%)、白内障10%(95%CI 7%-13%)、股骨头坏死8%(95%CI 5%-10%)、糖尿病5%(95%CI 3%-7%)、甲状腺功能减退3%(95%CI 2%-5%)。
  • 全身照射仅与白内障风险升高独立相关(HR 4.98,P<.0001)。
  • 慢性GVHD与白内障(HR 3.22,P=.0006)、股骨头坏死(HR 2.49,P=.006)和糖尿病(HR 3.36,P=.03)风险增加相关。
  • 10年总生存率和无白血病生存率分别为73%和70%,不因预处理类型而异。

临床怎么用

  • 对青少年及青年急性髓系白血病清髓性移植后1年无病生存者应长期监测远期效应,尤其关注慢性GVHD患者。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is marked paucity of data regarding late effects in adolescents and young adults (AYAs) who undergo myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). We evaluated late effects and survival in 826 1-year disease-free survivors of MAC HCT for AYA AML, with an additional focus on comparing late effects based upon MAC type (total body irradiation [TBI] vs high-dose chemotherapy only). The estimated 10-year cumulative incidence of subsequent neoplasms was 4% (95% confidence interval [CI], 2%-6%); 10-year cumulative incidence of nonmalignant late effects included gonadal dysfunction (10%; 95% CI, 8%-13%), cataracts (10%; 95% CI, 7%-13%), avascular necrosis (8%; 95% CI, 5%-10%), diabetes mellitus (5%; 95% CI, 3%-7%), and hypothyroidism (3%; 95% CI, 2%-5%). Receipt of TBI was independently associated with a higher risk of cataracts only (hazard ratio [HR], 4.98; P < .0001) whereas chronic graft-versus-host disease (cGVHD) was associated with an increased risk of cataracts (HR, 3.22; P = .0006), avascular necrosis (HR, 2.49; P = .006), and diabetes mellitus (HR, 3.36; P = .03). Estimated 10-year overall survival and leukemia-free survival were 73% and 70%, respectively, and did not differ on the basis of conditioning type. In conclusion, late effects among survivors of MAC HCT for AYA AML are frequent and are more closely linked to cGVHD than type of conditioning.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lee CJ, Kim S, Tecca HR, et al. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020. PMID: 32168378. doi:10.1182/bloodadvances.2019001126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。